Table 4. Logistic regression analysis for early AF recurrence within 3 months of ECV.
| Univariate | Multivariate | |||
|---|---|---|---|---|
| OR (95% CI) | p value | OR (95% CI) | p value | |
| Age (years) | 0.99 (0.98–1.00) | 0.051 | 0.99 (0.96–1.01) | 0.278 |
| Male | 1.02 (0.81–1.29) | 0.870 | 1.18 (0.66–2.12) | 0.577 |
| BMI (kg/m2) | 1.00 (0.99–1.01) | 0.609 | - | - |
| AF duration (months) | 1.01 (1.00–1.01) | 0.006 | 1.01 (1.00–1.02) | 0.006 |
| Post-AFCA | 0.62 (0.44–0.88) | 0.007 | 0.42 (0.14–1.21) | 0.107 |
| CHA2DS2-VASc | 0.98 (0.92–1.05) | 0.587 | - | - |
| Heart failure | 0.90 (0.67–1.22) | 0.509 | - | - |
| Hypertension | 0.90 (0.74–1.11) | 0.331 | - | - |
| Diabetes | 1.06 (0.81–1.39) | 0.651 | - | - |
| Stroke | 1.16 (0.85–1.60) | 0.339 | - | - |
| Vascular disease | 0.75 (0.47–1.20) | 0.227 | - | - |
| LA dimension (mm) | 1.01 (0.99–1.03) | 0.207 | - | - |
| Ejection fraction (%) | 1.00 (0.99–1.01) | 0.472 | - | - |
| E/Em | 0.98 (0.96–1.00) | 0.069 | - | - |
| Successful ECV energy (J) | 1.24 (1.13–1.37) | <0.001 | 1.26 (1.00–1.60) | 0.052 |
| Antiarrhythmic drugs | 1.42 (0.81–2.48) | 0.220 | - | - |
| Amiodarone | 0.60 (0.49–0.74) | <0.001 | 0.46 (0.27–0.76) | 0.002 |
| ACEi/ARB | 0.58 (0.45–0.75) | <0.001 | 0.88 (0.48–1.63) | 0.690 |
| b-blocker | 0.82 (0.65–1.02) | 0.073 | - | - |
| Statin | 0.67 (0.52–0.88) | 0.003 | 0.92 (0.52–1.64) | 0.777 |
ACEi = angiotensin converting enzyme inhibitor; AF = atrial fibrillation; AFCA = atrial fibrillation catheter ablation; ARB, angiotensin receptor blocker; BMI = body mass index; CI = confidence interval; E = early diastolic mitral inflow velocity; ECV = elective external cardioversion; Em = early diastolic mitral annular velocity; LA = left atrial; OR = odds ratio.